# Bristol Myers Squibb

Breyanzi (lisocabtagene maraleucel, CD19) had its monitoring and activity update approved in Canada in June 2026, and BMS co-develops Abecma (idecabtagene vicleucel, BCMA) with 2seventy bio for multiple myeloma.

Source: https://en.bioecon.ru/companies/bristol-myers-squibb/
Updated: 2026-07-11

- Country: United States
- Ticker: BMY

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $48.2 billion in 2025 | https://www.bms.com/investors/financial-reporting/key-facts.html, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm |
| Headcount | ~5,000 (cell therapy operations) to 34,100 (total company) employees | https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/ |
| Production site | Devens, Massachusetts (cell therapy) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Production site | Bothell, Washington; Summit, New Jersey; Warren, New Jersey (cell therapy) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Production site | Leiden, Netherlands (cell therapy, in development/completed) | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |
| Regulatory approval | Breyanzi monitoring/activity update approved in Canada June 2026; U.S. label updates for Breyanzi and Abecma June 2025 | https://investors.bms.com/iframes/press-releases/press-release-details/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://news.bms.com/news/corporate-financial/2025/U-S--Food-and-Drug-Administration-Approves-Streamlined-Patient-Monitoring-Requirements-and-Removal-of-REMS-Programs-within-Bristol-Myers-Squibbs-Cell-Therapy-Labels/default.aspx, https://www.bms.com/assets/bms/ca/documents/productmonograph/BREYANZI_EN_PM.pdf, https://www.bms.com/ca/en/media/press-release-listing/2026-06-17-press-release.html, https://www.hematologyadvisor.com/news/fda-removes-rems-reduces-monitoring-requirements-for-breyanzi-and-abecma/ |
| Capacity | Expanding through new sites (Devens, Leiden) and innovative manufacturing solutions [medium confidence] | https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Receives-U.S.-FDA-Approval-of-New-State-of-the-Art-Cell-Therapy-Manufacturing-Facility-in-Devens-Massachusetts/default.aspx, https://www.bms.com/assets/bms/us/en-us/pdf/cell-therapy-operations-and-manufacturing-factsheet.pdf, https://www.contractpharma.com/top-company-profile/bristol-myers-squibb/, https://www.fiercepharma.com/manufacturing/bristol-myers-cell-manufacturing-site-mass-good-go-fda-says |

Independent sources: bms.com, contractpharma.com, fiercepharma.com, hematologyadvisor.com, investors.bms.com, news.bms.com, sec.gov

## Technologies

- [Biopharmaceuticals & biomedicines](https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/)
- [CAR-T cell therapy](https://en.bioecon.ru/technology/car-t-cell-therapy/)